SEC Form 4 · accession 0000899243-17-024257
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nancy T Chang
Director
Period of report
Oct 13, 2017
Accepted (ET)
Oct 16, 2017 · 5:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 13, 2017 | D | 70,000 | $11.18 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2,F1 | $9.15 | Oct 13, 2017 | D | 30,000 | D | — | Jun 11, 2025 | Common Stock | 30,000 | 0 | D |
| Non-Qualified Stock Option (right to buy)F2,F3 | $10.90 | Oct 13, 2017 | D | 30,000 | D | — | Jun 8, 2027 | Common Stock | 30,000 | 0 | D |
Explanation of responses
- F1Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016.
- F2The option was canceled immediately prior to the Merger in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.
- F3Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 8, 2017), and became immediately exercisable and vested in full as of the date ten (10) days prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger").